Shares of Acurx Pharmaceuticals, a small company specializing in the development of new antibiotics, fell 10% in after-hours trading on January 6 following the announcement of a planned secondary offering. The news dampened investor enthusiasm sparked earlier that day by regulatory approval of the company’s trial plan for its lead…